2.68
price up icon4.28%   0.11
after-market Dopo l'orario di chiusura: 2.75 0.07 +2.61%
loading
Precedente Chiudi:
$2.57
Aprire:
$2.5
Volume 24 ore:
16.63M
Relative Volume:
1.00
Capitalizzazione di mercato:
$894.94M
Reddito:
$32.77M
Utile/perdita netta:
$-440.22M
Rapporto P/E:
-1.6048
EPS:
-1.67
Flusso di cassa netto:
$-400.48M
1 W Prestazione:
-14.38%
1M Prestazione:
+54.02%
6M Prestazione:
-54.19%
1 anno Prestazione:
-67.16%
Intervallo 1D:
Value
$2.45
$2.71
Intervallo di 1 settimana:
Value
$2.45
$3.41
Portata 52W:
Value
$1.6385
$12.51

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name
Nome
Iovance Biotherapeutics Inc
Name
Telefono
(650) 260-7120
Name
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS
Name
Dipendente
838
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
IOVA's Discussions on Twitter

Confronta IOVA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
IOVA
Iovance Biotherapeutics Inc
2.68 858.21M 32.77M -440.22M -400.48M -1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-15 Downgrade Goldman Neutral → Sell
2025-05-16 Downgrade UBS Buy → Neutral
2025-05-12 Downgrade Truist Buy → Hold
2025-05-09 Downgrade Citizens JMP Mkt Outperform → Mkt Perform
2024-10-24 Iniziato UBS Buy
2024-07-29 Downgrade Piper Sandler Overweight → Neutral
2023-11-20 Iniziato Goldman Buy
2023-09-18 Reiterato Barclays Overweight
2023-05-30 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-03-27 Ripresa Wells Fargo Equal Weight
2023-01-27 Aggiornamento Piper Sandler Neutral → Overweight
2022-12-09 Downgrade Goldman Buy → Neutral
2022-10-31 Iniziato Guggenheim Neutral
2022-08-18 Ripresa Wells Fargo Equal Weight
2022-01-28 Aggiornamento Stifel Hold → Buy
2021-12-07 Ripresa Cowen Outperform
2021-06-10 Aggiornamento JMP Securities Mkt Perform → Mkt Outperform
2021-05-20 Downgrade Piper Sandler Overweight → Neutral
2021-05-19 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2021-05-19 Downgrade Stifel Buy → Hold
2021-05-03 Iniziato Truist Buy
2021-04-16 Iniziato Goldman Buy
2021-03-08 Aggiornamento H.C. Wainwright Neutral → Buy
2020-12-15 Downgrade H.C. Wainwright Buy → Neutral
2020-10-06 Downgrade Wells Fargo Overweight → Equal Weight
2020-04-22 Iniziato Mizuho Buy
2020-03-04 Iniziato Barclays Overweight
2020-02-26 Reiterato H.C. Wainwright Buy
2020-02-26 Reiterato Oppenheimer Outperform
2019-12-18 Iniziato JMP Securities Mkt Outperform
2019-10-01 Iniziato Stifel Buy
2019-04-29 Iniziato Piper Jaffray Overweight
2019-02-28 Reiterato Chardan Capital Markets Buy
2019-02-07 Iniziato Robert W. Baird Outperform
2018-12-31 Ripresa B. Riley FBR Buy
2018-07-06 Reiterato Chardan Capital Markets Buy
2018-04-10 Aggiornamento B. Riley FBR, Inc. Neutral → Buy
2018-03-13 Reiterato B. Riley FBR, Inc. Neutral
2018-02-23 Downgrade B. Riley FBR, Inc. Buy → Neutral
2018-01-25 Reiterato H.C. Wainwright Buy
2017-11-01 Reiterato B. Riley FBR, Inc. Buy
Mostra tutto

Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie

pulisher
Aug 03, 2025

Is Iovance Biotherapeutics Inc. stock overvalued or undervaluedMarket-leading growth rates - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

What are Iovance Biotherapeutics Inc. company’s key revenue driversMassive wealth growth - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

Will Iovance Biotherapeutics Inc. price bounce be sustainableFree Early Entry Picks Before News Breakout - Newser

Aug 03, 2025
pulisher
Aug 02, 2025

What institutional investors are buying Iovance Biotherapeutics Inc. stockAchieve consistent profits with proven strategies - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

What are the latest earnings results for Iovance Biotherapeutics Inc.Invest smarter with actionable trading signals - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 01, 2025

What is the dividend policy of Iovance Biotherapeutics Inc. stockStock Market Picks With High Returns - jammulinksnews.com

Aug 01, 2025
pulisher
Aug 01, 2025

A Closer Look at Iovance Biotherapeutics Inc (IOVA) Stock Gains - investchronicle.com

Aug 01, 2025
pulisher
Aug 01, 2025

Iovance Biotherapeutics: Unlocking TIL Therapy's Potential Amid Funding Challenges - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges - Yahoo Finance

Aug 01, 2025
pulisher
Aug 01, 2025

Day 6 of Loss Streak for Iovance Biotherapeutics Stock with -35% Return (vs. -65% YTD) [7/31/2025] - Trefis

Aug 01, 2025
pulisher
Aug 01, 2025

Iovance Biotherapeutics (IOVA) Gets Downgraded to Sell from Neutral at Goldman Sachs - MSN

Aug 01, 2025
pulisher
Aug 01, 2025

Intraday pattern recognizer results for Iovance Biotherapeutics Inc.Real-Time Setup Summary with ROI Focus - Newser

Aug 01, 2025
pulisher
Jul 31, 2025

Iovance Biotherapeutics: Recent Clinical Study Results and Leadership Appointments Boost Growth Prospects - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

Iovance Biotherapeutics shares rise 4.12% premarket after Eisai and Biogen's Alzheimer's drug LEQEMBI shows sustained long-term benefits. - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

Exit strategy if you’re trapped in Iovance Biotherapeutics Inc.Chart Driven Entry Timing for Swing Trades - Newser

Jul 31, 2025
pulisher
Jul 31, 2025

What is the risk reward ratio of investing in Iovance Biotherapeutics Inc. stockEarnings Report Planner For 2025 - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

Iovance Biotherapeutics Inc. Building a Base Near SupportSwing Trade Entry Alert Analysis - beatles.ru

Jul 31, 2025
pulisher
Jul 31, 2025

What moving averages say about Iovance Biotherapeutics Inc.Real Time Growth Signal with Smart Setup - Newser

Jul 31, 2025
pulisher
Jul 31, 2025

Day 5 of Loss Streak for Iovance Biotherapeutics Stock with -33% Return (vs. -64% YTD) [7/30/2025] - Trefis

Jul 31, 2025
pulisher
Jul 30, 2025

Market Shock Waves: Iovance Biotherapeutics’ Sudden Challenges - timothysykes.com

Jul 30, 2025
pulisher
Jul 30, 2025

Iovance Biotherapeutics Faces Market Challenges Amid Financial Setbacks - StocksToTrade

Jul 30, 2025
pulisher
Jul 30, 2025

Is Iovance Biotherapeutics Stock Due for a Big Rally? - Mitrade

Jul 30, 2025
pulisher
Jul 30, 2025

Using AI based signals to follow Iovance Biotherapeutics Inc.Chart Pattern Recognition for Profit Timing - Newser

Jul 30, 2025
pulisher
Jul 30, 2025

Can Iovance Biotherapeutics Inc. rally from current levelsShort-Term Profit Alert With Entry Forecast - newser.com

Jul 30, 2025
pulisher
Jul 30, 2025

How to monitor Iovance Biotherapeutics Inc. with trend dashboardsReliable Setup Screener with Low Risk - Newser

Jul 30, 2025
pulisher
Jul 29, 2025

Is Iovance Biotherapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideFree Optimized Watchlist With Daily Adjustments - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 18:47:39 - beatles.ru

Jul 29, 2025
pulisher
Jul 29, 2025

Why Iovance Biotherapeutics Inc. stock attracts strong analyst attentionReal Time Trade Execution Alert Plan - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

Iovance Biotherapeutics Inc. Company Revenue and Profit Trends: A Deep DiveWatchlist for Low Risk High Return Stocks Updated - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Price momentum metrics for Iovance Biotherapeutics Inc. explainedMomentum Prediction Based on AI Backtesting - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

Is Iovance Biotherapeutics a Buy on the Dip? Assessing the Risk/Reward of Autologous Cell Therapy Commercialization - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

Iovance Biotherapeutics shares rise 2.03% premarket after UK's MHRA approves Tofersen for rare motor neurone disease. - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy? - Yahoo Finance

Jul 29, 2025
pulisher
Jul 28, 2025

Iovance Biotherapeutics’ SWOT analysis: stock faces challenges amid promising data - Investing.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are the technical indicators suggesting about Iovance Biotherapeutics Inc.Turbocharged investment results - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Does Iovance Biotherapeutics Inc. stock perform well during market downturnsRecord-breaking capital gains - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How Iovance Biotherapeutics Inc. stock performs during market volatilitySwing Entry Risk Mitigation with Chart Analysis - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

What are analysts’ price targets for Iovance Biotherapeutics Inc. in the next 12 monthsSkyrocketing profit margins - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

Is Iovance Biotherapeutics Inc. Stock a Good Fit for Conservative InvestorsDaily Top Gainers - metal.it

Jul 27, 2025
pulisher
Jul 27, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Acquired by Bank of New York Mellon Corp - Defense World

Jul 27, 2025
pulisher
Jul 27, 2025

Levi & Korsinsky Notifies Shareholders of Iovance Biotherapeutics, Inc.(IOVA) of a Class Action Lawsuit and an Upcoming Deadline - Kilgore News Herald

Jul 27, 2025
pulisher
Jul 25, 2025

Iovance Biotherapeutics Plummets Amidst Lawsuit and Executive Shake-up - timothysykes.com

Jul 25, 2025
pulisher
Jul 25, 2025

Decoding Iovance Biotherapeutics: A TIL Breakout or Premature Optimism? - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

Iovance Biotherapeutics Is Waking UpPrice Action Screams Breakout, But Fundamentals Demand Patience - Seeking Alpha

Jul 25, 2025
pulisher
Jul 25, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Held Back By Insufficient Growth Even After Shares Climb 75% - 富途牛牛

Jul 25, 2025
pulisher
Jul 25, 2025

Iovance Biotherapeutics Soars 13.37% on FDA Approval, Buy Rating - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Iovance Biotherapeutics Inc. stockUnprecedented market success - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Iovance Biotherapeutics shares rise 5.47% premarket after Pfizer's $1.25 billion licensing agreement for cancer drug. - AInvest

Jul 25, 2025
pulisher
Jul 24, 2025

Iovance Biotherapeutics to Host Second Quarter and First - GlobeNewswire

Jul 24, 2025
pulisher
Jul 24, 2025

About Us - FinancialContent

Jul 24, 2025
pulisher
Jul 24, 2025

Goldman Sachs Downgrade Sends Iovance Biotherapeutics Tumbling - timothysykes.com

Jul 24, 2025

Iovance Biotherapeutics Inc Azioni (IOVA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Capitalizzazione:     |  Volume (24 ore):